NCT06994286View on ClinicalTrials.gov

The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 24, 2025

Primary Completion Date

July 21, 2025

Study Completion Date

August 4, 2025

Conditions
Healthy Subjects
Interventions
DRUG

MT-7117

Oral

DRUG

Placebo

Oral

Trial Locations (1)

100029

Beijing Anzhen Hospital, Capital Medical University, Beijing

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY